Rheumatoid arthritis

Reduction of Cardiovascular Disease and Mortality Versus Risk of New‐Onset Diabetes Mellitus With Statin Use in Patients With Rheumatoid Arthritis

Arthritis Care Res (Hoboken)Published Retrospective cohort study

Authors' conclusion

Statins are associated with important reductions in CVD and mortality that outweigh the modest increase in type 2 DM risk in RA patients.

Study context

Population
Patients with Rheumatoid Arthritis (RA), UK Clinical Practice Research Datalink, 1989–2018
Participants
1,768 vs 3,528
Exposure
Statin initiators vs matched concurrent nonusers
  • Statinn = 1,768
  • Nonusersn = 3,528reference
Outcome
Composite cardiovascular disease (CVD) (MI, stroke, hospitalised HF or CVD mortality), all-cause mortality and incident type 2 DM
Methodological detailsprevalent new-user cohort design, matched 1:2 by time-conditional propensity score, as-treated, Cox proportional hazards model
  • Prevalent new-user cohort design
  • Matched 1:2 by time-conditional propensity score
  • As-treated
  • Cox proportional hazards model

Main finding

As reported in the abstract

Composite CVD:
  • MI
  • Stroke
  • Hospitalised HF
  • CVD mortality

Hazard ratio

0.68

95% CI 0.51–0.90

Events by group

Observational data: associations, not effects.

Further findings

Per 100 person-years

OutcomeStatinNonusersHR (95% CI)
All-cause mortality54% reduction; NNT in 1 year 422.84.10.46 (0.35–0.60)

Safety

Per 100 person-years

OutcomeStatinNonusersHR (95% CI)
Incident type 2 DM33% increase; NNH in 1 year 1273.02.01.33 (1.09–1.63)
  • Incident type 2 diabetes mellitus (DM): DM cohort: 3,608 statin initiators and 7,208 nonusers

Original publication

Reduction of Cardiovascular Disease and Mortality Versus Risk of New‐Onset Diabetes Mellitus With Statin Use in Patients With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). Published 17 November 2022. doi:10.1002/acr.24866

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.